PTC Therapeutics named a new top pick at Credit Suisse Credit Suisse said PTC Therapeutics is a new top pick following the recent CHMP recommendation. The firm expects PTC to launch Translarna in the EU in 2H and and views it as a potential billion-dollar drug. Shares are Outperform rated with a $40 price target.
PTC Therapeutics CEO no longer owns company shares, TheStreet says PTC Therapeutics CEO Stu Peltz sold the remaining 47,200 shares he owned in the company, TheStreet's Adam Feuerstein reports, citing a regulatory filing yesterday. The sale follows a stock rise in part fueled by takeover speculation, Feuerstein adds. Reference Link